MUC1 and hepatocellular carcinoma: Targeting MUC1 by antibody-derived chimeric antigen receptor (CAR) T or CAR-pNK therapies is the purpose of phase I/II trials in patients with MUC1 positive relapsed or refractory solid tumors, including HCC.